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The household use of some of the organo-
phosphate (OP) insecticides has been
restricted in recent years after findings of
neurodevelopmental toxicity and unpre-
dicted environmental persistence [U.S.
Environmental Protection Agency (EPA)
2000, 2002]. In spite of these constraints,
chlorpyrifos (CPF) and diazinon (DZN)
each continue to be applied in agriculture at
rates > 10 million pounds annually (U.S.
EPA 2004, 2006). In animal models, devel-
opmental neurotoxicity results from either
CPF or DZN at doses that do not elicit any
signs of systemic intoxication and even at
exposures below the threshold for inhibition
of acetylcholinesterase (AChE), which is
often considered to be the primary target for
OPs (Slotkin 1999, 2004, 2005; Slotkin
et al. 2006a, 2006b). Because pregnant
women are likely to be exposed to OPs
under circumstances that do not elicit out-
ward signs of intoxication (De Peyster et al.
1993; Gurunathan et al. 1998; Ostrea et al.
2002) and in light of recent findings that
such exposures can produce long-term cog-
nitive impairment in their children (Rauh
et al. 2006; Rohlman et al. 2005), the mech-
anisms and consequences of OP-induced
developmental neurotoxicity remain a major
environmental concern.
The systemic toxicity of OPs reflects the
symptoms related to cholinergic hyper-
stimulation consequent to the irreversible loss
of AChE catalytic activity, which typically
emerges when inhibition exceeds 70% (Clegg
and van Gemert 1999). In contrast, CPF and
DZN both elicit adverse effects on brain
development at much lower exposures, and the
adverse effects involve the native compounds
and not their hepatically produced oxon
metabolites, which are the actual agents that
cause irreversible AChE inhibition (Slotkin
1999, 2004, 2005; Slotkin et al. 2006a,
2006b). Nevertheless, AChE itself may be
involved in these effects through mechanisms
unrelated to its catalytic activity and therefore
separable from “cholinergic” effects. As a struc-
tural protein, AChE appears to play an impor-
tant role in axonal outgrowth (Bigbee et al.
2000), synaptogenesis (Sternfeld et al. 1998),
cell adhesion (Bigbee and Sharma 2004), and
neuronal migration (Byers et al. 2005; Dori
et al. 2005), functions that are largely indepen-
dent of the enzymatic ability to hydrolyze ACh
(Soreq and Seidman 2001). It is critical to note
that these nonenzymatic functions differ
among the AChE isoforms and/or their cleav-
age products (Dori et al. 2005; Grifman et al.
1998; Sternfeld et al. 1998). The open reading
frame of the AChE gene comprises ﬁve exons,
of which exons 2, 3, and 4 contain the cat-
alytic subunits and are invariantly spliced
(Figure 1). Alternate splicing of the last two
exons and their associated introns results in at
least three variants of the mRNA, two of
which are expressed in the central nervous sys-
tem. The most abundant “synaptic” isoform
(AChE-S) is typically tetrameric and mem-
brane-bound in the synapse, where it performs
the bulk of ACh hydrolysis, whereas as a much
rarer “read-through” variant (AChE-R)—so
called because it results from inclusion of
intron 4—is soluble and monomeric. In gen-
eral, although both AChE isoforms are
inducible by cholinesterase inhibitors or by
neural injury, the expression of AChE-R
appears to be related to neuroprotection and
repair, whereas AChE-S, either by itself or
when up-regulated in conjunction with
AChE-R, is more highly associated with injury
and increasing neurotoxicity (Cohen et al.
2002; Perrier et al. 2005; Shohami et al. 2000;
Sternfeld et al. 2000). In this context, over-
expression of AChE-S produces aberrant den-
dritic morphology and neuronal fragmentation
(Sternfeld et al. 2000). Accordingly, recent
studies have explored the roles of the two
AChE variants in the response to neuronal
injury and neurodegeneration (Perrier et al.
2005; Sternfeld et al. 2000), physical trauma
(Shohami et al. 2000), and Alzheimer disease
(Darreh-Shori et al. 2004).
Cholinesterase inhibitors, including the
OPs, are known to increase the overall expres-
sion of AChE and to alter the relative expres-
sion of AChE-R and AChE-S in the adult
brain (Damodaran et al. 2003; Darreh-Shori
et al. 2004; Friedman et al. 1996; Meshorer
et al. 2002; Salmon et al. 2005). In the present
study, we explored the corresponding effects in
the developing nervous system to evaluate the
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BACKGROUND: Organophosphate pesticides affect mammalian brain development through mecha-
nisms separable from the inhibition of acetylcholinesterase (AChE) enzymatic activity and resultant
cholinergic hyperstimulation. In the brain, AChE has two catalytically similar splice variants with
distinct functions in development and repair. The rare, read-through isoform, AChE-R, is preferen-
tially induced by injury and appears to promote repair and protect against neurodegeneration.
Overexpression of the more abundant, synaptic isoform, AChE-S, enhances neurotoxicity. 
OBJECTIVES: We exposed differentiating PC12 cells, a model for developing neurons, to 30 µM
chlorpyrifos (CPF) or diazinon (DZN), or CPF oxon, the active metabolite that irreversibly inhibits
AChE enzymatic activity, in order to determine whether they differentially induce the formation of
AChE-S as a mechanistic predictor of developmental neurotoxicity. We then administered CPF or
DZN to neonatal rats on postnatal days 1–4 using daily doses spanning the threshold for AChE
inhibition (0–20%); we then evaluated AChE gene expression in forebrain and brainstem on post-
natal day 5. 
RESULTS: In PC12 cells, after 48 hr of exposure, CPF, CPF oxon, and DZN enhanced gene expres-
sion for AChE-R by about 20%, whereas CPF and DZN, but not CPF oxon, increased AChE-S
expression by 20–40%. Thus, despite the fact that CPF oxon is a much more potent AChE
inhibitor, it is the native compound (CPF) that induces expression of the neurotoxic AChE-S iso-
form. For in vivo exposures, 1 mg/kg CPF had little or no effect, but 0.5 or 2 mg/kg DZN induced
both AChE-R and AChE-S, with a greater effect in males. 
CONCLUSIONS: Our results indicate that nonenzymatic functions of AChE variants may participate
in and be predictive of the relative developmental neurotoxicity of organophosphates, and that the
various organophosphates differ in the degree to which they activate this mechanism.
KEY WORDS: acetylcholinesterase, brain development, chlorpyrifos, diazinon, organophosphate
insecticides, PC12 cells. Environ Health Perspect 115:65–70 (2007). doi:10.1289/ehp.9487 avail-
able via http://dx.doi.org/ [Online 11 October 2006]potential contribution of nonenzymatic func-
tion of AChE splice variants as a target for the
developmental neurotoxicity of OPs. First, we
made use of PC12 cells, an in vitro model of
neuronal development that has proven espe-
cially useful for evaluations of developmental
neurotoxicants, including the OPs (Crumpton
et al. 2000; Das and Barone 1999; Fujita et al.
1989; Jameson et al. 2006; Madhok and Sharp
1992; Qiao et al. 2001, 2005; Song et al.
1998; Teng and Greene 1994). Upon addition
of nerve growth factor (NGF), PC12 cells
begin to differentiate and develop axonal pro-
jections and electrical excitability, along with
the properties of cholinergic neurons, includ-
ing increased expression of AChE (Das and
Barone 1999; Fujita et al. 1989; Greene and
Rukenstein 1981; Teng and Greene 1994). In
this model, we compared the effects of CPF
and DZN to that of CPF oxon (CPO), which
is three orders of magnitude more potent
toward inhibition of AChE than the parent
compound, CPF (Das and Barone 1999).
Next, we compared CPF to DZN in develop-
ing rats given treatment with either agent on
postnatal days (PND) 1–4, using doses span-
ning the threshold for AChE inhibition that
are known to evoke neurodevelopmental
deficits without signs of systemic toxicity
(Slotkin 1999, 2004, 2005; Slotkin et al.
2006a, 2006b). Because the two AChE iso-
forms share the common catalytic domain
and therefore hydrolyze acetylcholine with
similar efﬁciency (Sternfeld et al. 1998), enzy-
matic techniques cannot distinguish AChE-R
from AChE-S, so instead, we evaluated the
differential effects on expression of mRNAs
encoding the two variants, using standard
reverse transcriptase-polymerase chain reaction
(RT-PCR) methods.
Methods
PC12 cell cultures. Because of the clonal insta-
bility of the PC12 cell line (Fujita et al. 1989),
the experiments were performed on cells that
had undergone fewer than ﬁve passages, and
all experiments were repeated with multiple
batches of cells. As described previously
(Crumpton et al. 2000; Qiao et al. 2003; Song
et al. 1998), PC12 cells (American Type
Culture Collection, 1721-CRL; obtained from
the Duke University Comprehensive Cancer
Center, Durham, NC) were seeded onto
100-mm poly-D-lysine–coated plates (approxi-
mately 3 × 106 cells/plate) in RPMI-1640
medium (Invitrogen, Carlsbad, CA) supple-
mented with 10% inactivated horse serum
(Sigma Chemical Co., St. Louis, MO), 5%
fetal bovine serum (Sigma Chemical Co.),
and 50 μg/mL penicillin streptomycin
(Invitrogen); cells were incubated with 7.5%
CO2 at 37°C. Twenty-four hours after seed-
ing, the medium was changed to include
50 ng/mL 2.5 S murine NGF (Invitrogen),
along with CPF, CPO, or DZN (Chem
Service, West Chester, PA). The OP agents
were dissolved in dimethylsulfoxide (DMSO;
Sigma Chemical Co.), achieving a final
DMSO concentration of 0.1% in the culture
medium, and the corresponding control sam-
ples contained equivalent DMSO concentra-
tions. This concentration of DMSO has no
effect on PC12 cells (Qiao et al. 2001, 2003;
Song et al. 1998). Samples were then incu-
bated for 48 hr in the continuous presence of
each agent and NGF. We evaluated the effects
of 30 μM CPF, CPO, or DZN, a concentra-
tion known to produce adverse effects on cell
replication and differentiation (Crumpton
et al. 2000; Jameson et al. 2006; Qiao et al.
2001; Song et al. 1998); in addition, we evalu-
ated a 1,000× lower concentration of CPO
(30 nM) in light of its correspondingly higher
potency as an AChE inhibitor (Das and
Barone 1999).
Animal treatments. All animal experiments
were approved by the Duke University Animal
Care and Use Committee and were carried out
in accordance with all federal and state stan-
dards of care; animals were treated humanely
and with regard for alleviation of suffering.
Timed-pregnant Sprague-Dawley rats (Charles
River, Raleigh, NC) were housed in breeding
cages, with a 12-hr light/dark cycle and free
access to food and water. On the day of birth,
all pups were randomized and redistributed to
the dams with a litter size of 9–10 to maintain
a standard nutritional status. 
CPF and DZN were dissolved in DMSO
to provide consistent absorption (Whitney
et al. 1995) and were injected subcutaneously
in a volume of 1 mL/kg once daily on
PND1–4; control animals received equivalent
injections of the DMSO vehicle. For both
agents, we used doses below the threshold for
growth retardation and systemic toxicity
(Campbell et al. 1997; Slotkin et al. 2006a;
Whitney et al. 1995): 1 mg/kg CPF and 0.5 or
2 mg/kg DZN. This CPF treatment and the
higher dose of DZN produce neurotoxicity in
developing rat brain while eliciting < 20%
AChE inhibition, well below the 70% thresh-
old necessary for symptoms of cholinergic
hyperstimulation (Clegg and van Gemert
1999); the lower dose of DZN is below the
threshold for detectable AChE inhibition
(Slotkin 1999, 2004; Slotkin et al. 2006b;
Song et al. 1997; Whitney et al. 1995). These
treatments thus resemble the nonsymptomatic
exposures reported in pregnant women
(De Peyster et al. 1993) and are within the
range of expected fetal and childhood expo-
sures after routine home application or in agri-
cultural communities (Gurunathan et al. 1998;
Ostrea et al. 2002). On PND5 (24 hr after the
last dose), one male and one female pup were
selected from each of six litters in each treat-
ment group and were used for evaluations.
Animals were decapitated, the cerebellum
(which is sparse in acetylcholine projections)
was removed, and the rest of the brain was
separated into brainstem and forebrain
(regions containing the majority of acetyl-
choline projections) by a cut made rostral to
the thalamus. Tissues were weighed and ﬂash-
frozen in liquid nitrogen and maintained at
–45°C until analyzed. None of the treatments
led to changes in weight of body or brain
region, and there was no loss of viability.
AChE variant analysis by RT-PCR. Total
RNA was extracted using the Aurum Total
RNA Fatty and Fibrous Tissue Kit (Bio-Rad
Laboratories, Hercules, CA), following the
manufacturer’s protocol, yielding approxi-
mately 1 μg total RNA per milligram tissue.
We veriﬁed the integrity of the RNA by ethid-
ium bromide staining of the ribosomal bands
isolated by standard electrophoresis in agarose,
and determined the concentration and purity.
PCR ampliﬁcation was performed using stan-
dard commercial reagent kits (Invitrogen). A
5-μg aliquot of each RNA sample was reverse-
transcribed with Superscript III using random
hexamer primers. The isoforms were ampliﬁed
in separate PCR reactions using primers
designed for each specific splice variant
(Table 1). Because the expression of cyto-
skeletal and metabolic genes changes during
neuronal development, the typical, constitu-
tively expressed mRNAs (“housekeeping
genes”) were inappropriate for use as internal
standards. Instead, we used QuantumRNA
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Figure 1. AChE isoforms resulting from alternative splicing of the AChE pre-mRNA. Abbreviations: E, exon;
For, forward; I, intron; Rev, reverse. The AChE-R variant mRNA is the product of splicing and includes
intron (I) 4 and omits exon (E) 6. AChE-S omits intron 4 and extends through exon 6. Arrows represent
primers used in PCR detection of each splice variant.
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–R For –S RevClassic 18S Internal Standard Primers (Ambion
Inc., Austin, TX), which amplify a portion of
the 18S ribosomal subunit. This standard can
be titrated to generate a consistent PCR signal
across different numbers of cycles by altering
the ratio of 18S primers and competimers, the
latter of which inhibit primer binding to the
recognition sequence. The mRNA encoding
the AChE-R variant is present in very low con-
centrations relative to that for AChE-S or other
mRNAs (Perrier et al. 2005). Accordingly, we
used different primer:competimer ratios for the
two splice variants: 1:19 for AChE-R, and 1:4
for AChE-S. PCR reaction parameters were
optimized such that both the AChE and 18S
sequences were ampliﬁed in the linear range.
The annealing temperature used for both
isoforms was 55°C.
PCR products were quantified by elec-
trophoresis of 10 μL of product on 1.5%
agarose gels using Certified PCR Agarose
(BioRad) containing 0.3 μg/mL ethidium
bromide. Gel images were digitized and bands
were quantified using NIH Image Software
(National Institutes of Health 2006). Images
were uniformly calibrated to an optical den-
sity step tablet, and the background was
reduced with a rolling ball radius of 50.
AChE band values for each isoform had the
background subtracted and were then nor-
malized to the corresponding 18S band for
each sample.
Data analysis. Data are presented as
means and SEs, and treatment effects were
evaluated by multivariate analysis of variance
(ANOVA) incorporating all relevant factors:
for the in vitro studies, treatment (control,
CPF 30 μM, DZN 30 μM, CPO 30 μM,
CPO 30 nM) and AChE subtype (AChE-R,
AChE-S); for the in vivo studies, treatment
(control, CPF 1 mg/kg, DZN 0.5 mg/kg,
DZN 2 mg/kg), brain region (brainstem,
forebrain), sex (male, female), and subtype
(AChE-R, AChE-S). Lower-order tests were
conducted as permitted by the interactions of
treatment with other variables; however,
where treatment did not interact with another
variable, only main treatment effects are
reported without further subdivision. For
convenience, results are shown as the percent
change from corresponding control values,
but statistical evaluations were always con-
ducted on the original data (log-transformed
whenever the variance between groups was
heterogeneous). Because each set of primers
has distinct binding properties and requires
different cycle parameters, values for different
treatments are comparable for each splice vari-
ant alone, but comparing absolute values of the
two variants to each other is not meaningful.
Signiﬁcance was assumed at p < 0.05.
Results
The RT-PCR strategy yielded single products
of the anticipated molecular weights for both
of the AChE isoforms and for the ribosomal
18S internal standards (Figure 2). Amplifi-
cation of the AChE-R splice variant required at
least ﬁve cycles more than were necessary for
detection of the AChE-S variant, consistent
with its much lower abundance, even under
conditions that increase expression (Perrier
et al. 2005).
In vitro studies. In control PC12 cells,
expression values for the two AChE variants
(ratio to 18S ribosomal RNA; see “Methods”)
were 0.42 ± 0.02 for AChE-R and 0.51 ± 0.01
for AChE-S. As expected from earlier in vivo
work with nerve gas OPs (Damodaran et al.
2003; Soreq and Seidman 2001), treatment of
differentiating PC12 cells with CPF, DZN, or
CPO evoked increases in AChE mRNA
(Figure 3). At a CPF concentration of 30 μM,
the mRNAs encoding both AChE-R and
AChE-S exhibited increases of about 20%,
whereas for DZN, the same concentration
elicited greater induction (30% and 40%,
respectively). Because CPO is approximately
1,000 times more potent than CPF as an
AChE inhibitor (Das and Barone 1999), we
ﬁrst examined a concentration of 30 nM and
found a smaller effect on AChE-R expression,
intermediate between control levels and the
higher values evoked by 30 μM CPF or DZN.
Increasing the CPO concentration to 30 μM
produced an effect similar to that of equimolar
concentrations of CPF or DZN. Strikingly,
CPO was totally ineffective in increasing
AChE-S, even at the higher concentration.
In vivo studies. In control rats, the values
(ratio to 18S ribosomal RNA; see “Methods”)
for expression of the AChE subtypes were as
follows: for AChE-R, 1.83 ± 0.12 in male
brainstem, 1.67 ± 0.29 in female brainstem,
1.38 ± 0.05 in male forebrain, and 1.65 ± 0.26
in female forebrain; for AChE-S, 0.77 ± 0.03,
0.94 ± 0.03, 0.35 ± 0.02, and 0.65 ± 0.02,
respectively. Whereas there was no statistically
signiﬁcant sex difference for AChE-R, the dif-
ference for AChE-S was highly significant:
p < 0.0001 for the main effect of sex and
p < 0.0001 for the interaction of sex × region,
with the main effect of sex significant both
for brainstem (p < 0.004) and forebrain
(p < 0.0001).
Daily treatment of neonatal rats with
1 mg/kg CPF evoked slight increments in
AChE-R expression in brainstem and fore-
brain of male rats (Figure 4A), an effect that
did not achieve statistical signiﬁcance (no sig-
nificant main treatment effect or interaction
of treatment × region). In contrast, DZN,
either at 0.5 or 2 mg/kg, had more robust
effects, producing significant increments
(p < 0.03 and p < 0.04 respectively for main
treatment effects), with preferentially greater
effects in males (p < 0.02 for the main treat-
ment effect) than in females (not signiﬁcant).
Similarly, for AChE-S (Figure 4B), DZN
evoked significant increases in expression at
either 0.5 or 2 mg/kg (p < 0.05 and p < 0.003
for main treatment effects), but the effects for
Developmental neurotoxicity of organophosphates
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Table 1. Primers and conditions for RT-PCR analysis of AChE splice variants.
Product  Cycles for  Cycles for 
AChE variant Primers length PC12 samples brain samples
AChE-R Forward: 5´-CCCTCACTGAACTACACCGTGGAG-3´ 327 bp 29 34
Reverse: 5´-GTCCTTCCAACCCTTGCCGCCTTG-3´
AChE-S Forward: 5´-CCCTCACTGAACTACACCGTGGAG-3´ 310 bp 24 29
Reverse: 5´-CGGCCTTCCACTGGCGCTCC-3´
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Figure 2. Sample gel lanes from a representative
PC12 cell determination of AChE-R, AChE-S, and a
DNA standard ladder. The upper band in the sample
lanes is the 18S ribosomal control; the standard DNA
ladder consists of increments of 100 base pairs.
Figure 3. Effects of organophosphate treatment
(CPF, DZN, CPO) on AChE mRNA splice variants in
differentiating PC12 cells. Cells were treated for
48 hr in the presence of NGF. Data represent
means and SEs obtained from 6–12 cultures for
each condition, presented as the percent change
from control values. Across both variants, ANOVA
indicates a significant main treatment effect
(p < 0.0001) and a difference in treatment effects
between the two variants (treatment × subtype
interaction, p < 0.0005). For each variant, there was
a main treatment effect (p < 0.002 for AChE-R and
p < 0.0001 for AChE-S).
*Differs signiﬁcantly from the corresponding control.
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CPF DZN CPO CPF DZNCPF were insufficient to achieve statistical
significance; again, the effects of DZN in
males (p < 0.05 for the main treatment effect)
exceeded those in females (not significant).
The effects of either dose of DZN were statis-
tically distinguishable from the smaller effect
of CPF (p < 0.02 and p < 0.01 for comparison
with 0.5 or 2 mg/kg DZN, respectively). The
treatment effects in the brainstem were not
signiﬁcantly different from those in the fore-
brain (no treatment × region interaction), so
only main treatment effects are reported.
Discussion
Earlier work in adults showed that doses of
OPs high enough to elicit signs of systemic
toxicity can regionally up-regulate AChE
expression speciﬁcally involving the AChE-R
variant, which is associated with repair
mechanisms (Damodaran et al. 2003; Kaufer
et al. 1998; Perrier et al. 2005; Sternfeld et al.
2000), thus mimicking the sequelae of stress
(Meshorer et al. 2002) and head injury
(Shohami et al. 2000). The present results in
developing neuronotypic cells in vitro and in
neonatal rat brain regions in vivo indicate
that, during development, exposures to OPs
instead elicit a pattern associated with pro-
gressive neurotoxicity, namely co-induction
of both AChE-R and AChE-S (Cohen et al.
2002; Perrier et al. 2005; Shohami et al.
2000; Sternfeld et al. 2000); more speciﬁcally,
our in vivo ﬁndings indicate that this pattern
emerges in the developing brain even with
lower, nonsymptomatic exposures. Equally
important, our results support the idea that
the increases in AChE expression—especially
that of AChE-S, the critical factor that deter-
mines the balance between repair and neuro-
toxicity—are unrelated to the ability of the
OPs to inhibit catalytic activity. First, in dif-
ferentiating PC12 cells, 30 μM CPF, DZN,
or CPO all produced equivalent increases in
the expression of the AChE-R variant, despite
the fact that CPO is orders of magnitude
more potent in inhibiting catalytic activity
(Das and Barone 1999); lowering CPO to
30 nM, the biologically equivalent concentra-
tion for comparison with CPF and DZN,
lowered the AChE-inductive response below
that of the other OPs. Second, and even more
critically, whereas CPF was as effective and
DZN more effective in inducing AChE-S as
it was for AChE-R, CPO failed to evoke any
AChE-S increase whatsoever. Third, we
found virtually identical patterns after neo-
natal rats were exposed in vivo to DZN regi-
mens that evoke only minimal cholinesterase
inhibition and no systemic signs of its atten-
dant biologic effect, namely cholinergic
hyperstimulation; as was true for the PC12
cells, CPF was less effective than DZN.
Although the majority of work on the
developmental neurotoxicity of OPs has cen-
tered around the effects of CPF (Pope 1999;
Slotkin 1999, 2004, 2005), recent evidence
implicates a similar spectrum of actions for
DZN (Abu-Qare and Abou-Donia 2001;
Aluigi et al. 2005; Axelrad et al. 2002;
Paraoanu et al. 2006; Qiao et al. 2001; Slotkin
et al. 2006a, 2006b). Our results for effects on
AChE variants in PC12 cells reinforce the
similarity between CPF and DZN but also
point to an important potential difference: at
equimolar concentrations, DZN had a greater
effect and, specifically, a greater preferential
up-regulation of AChE-S. Although DZN
may produce more persistent inhibition of
AChE catalytic activity in the mature organ-
ism (Dembele et al. 2000), our results in the
in vivo study instead point to other mecha-
nisms that are responsible for induction of the
specific AChE isoforms in the developing
brain. Treatment of neonatal rats with
1 mg/kg CPF produces the same degree of
AChE inhibition as 2 mg/kg DZN, about
10–20% (Slotkin et al. 2006b; Song et al.
1997), well below the 70% threshold for the
emergence of any symptoms of intoxication
(Clegg and van Gemert 1999). Nevertheless,
as shown here, CPF had only marginal effects
on expression of AChE variants, whereas
DZN caused significant induction of both
AChE-R and AChE-S; again, as in the in vitro
study, DZN elicited the “neurotoxic” pattern,
coordinate up-regulation of both the read-
through and synaptic variants (Cohen et al.
2002; Perrier et al. 2005; Shohami et al. 2000;
Sternfeld et al. 2000). As further evidence of
the disconnection between inhibition of
AChE catalytic activity and the induction of
AChE transcripts, the higher dose of DZN
used here reduces AChE enzymatic activity
preferentially in females (Slotkin et al. 2006b),
whereas the effects on mRNAs encoding
AChE-R and AChE-S were greater in males.
Even more to the point, reducing the dose of
DZN to 0.5 mg/kg produced virtually an
equivalent effect on AChE isoform expression,
despite the fact that there is no inhibition of
catalytic activity whatsoever at the lower dose
(Slotkin et al. 2006b). Our results thus suggest
that, although CPF and DZN share the ability
to produce developmental neurotoxicity at
doses below the threshold for overt symptoms
of exposure, or even for inhibition of AChE
catalytic activity, DZN is far more likely to
activate neurotoxic events linked to the up-
regulation of AChE-S. We therefore anticipate
that, because of this additional component,
DZN may very well be more neurotoxic than
CPF in the developing brain. This prediction
is supported by two recent articles from our
group (Slotkin et al. 2006a, 2006b) and is cur-
rently being explored using microarray tech-
niques to detail the spectrum of gene families
involved in the comparative developmental
neurotoxicity of CPF and DZN. In any case,
our ﬁndings point to the necessity of examin-
ing gene splice variants that may be important
in the mechanisms or outcomes of OP-
induced developmental neurotoxicity, and not
just the total activity of the protein product.
The surprising dissimilarities between
CPF and CPO point to potential differences
in the mechanisms underlying their actions on
AChE catalytic activity versus gene expression.
CPO covalently binds with a reactive serine in
the AChE catalytic site, producing irreversible
inactivation. CPF or DZN, on the other
hand, do not form covalent bonds and thus
reversibly inhibit AChE by steric interaction
with the same site. Our ﬁnding that CPF and
DZN induce both AChE isoforms while CPO
Jameson et al.
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Figure 4. Effects of in vivo organophosphate treatment on AChE mRNA splice variants. (A) AChE-R.
(B) AChE-S. Animals were treated with CPF or DZN at the indicated doses on PND1–4, and samples were
obtained on PND5. Data represent mean and SE obtained from six animals of each sex in each treatment
group, presented as the percent change from the corresponding control values. Across both variants,
ANOVA indicates a signiﬁcant main treatment effect (p < 0.005), which was also signiﬁcant for each variant
separately (p < 0.03 for AChE-R; p < 0.02 for AChE-S). Differences in males were statistically significant
(p < 0.006), whereas those in females were not. Statistics for individual treatments whose main effects differ
from the corresponding control values are shown at the bottom of each panel; tests for individual regions
were not conducted because of the absence of treatment × region interactions. Note the difference in
scales in (A) and (B). NS, not signiﬁcant.
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AChE-R AChE-Sinduces only the AChE-R variant is in agree-
ment with findings from Alzheimer disease
therapeutics (Darreh-Shori et al. 2004). In
their study, Darreh-Shori et al. (2004) found
that the reversible AChE inhibitor, tacrine,
induced both AChE isoforms, whereas the
essentially irreversible inhibitor, rivastigmine,
mildly induced only the AChE-R isoform.
There is some evidence that the relevant inter-
actions actually involve a peripheral anionic
site on the molecule rather than the catalytic
center. Ligand binding to the peripheral site
can block access of substrates or allosterically
alter the catalytic efficiency of AChE, but
more importantly for our considerations, it
interferes with its nonenzymatic adhesion
functions that are required for axonogenesis
and other developmental events (Bourne et al.
2003; Johnson and Moore 2003; Kousba et al.
2004; Sentjurc et al. 1999). Although the OP
oxons have been explored for interactions with
the peripheral anionic site, our ﬁndings sug-
gest the potential importance of a comparative
examination of native OPs versus their oxons
to determine the extent to which this target
participates in developmental neurotoxicity.
We thus anticipate that the induction of
AChE variants associated with neurotoxicity
may require a different set of molecular inter-
actions from those elicited by covalent binding
of OP oxons to the catalytic site of AChE.
Finally, if the expression pattern of AChE
variants plays a role in the developmental
neurotoxicity of OPs, then, based on our ﬁnd-
ings, it would be expected that males would be
affected to a greater extent by the DZN
in vivo treatment regimens examined here.
Indeed, this prediction is consistent with ear-
lier results for effects of CPF on neuronal
structural proteins (Garcia et al. 2003), for
long-term changes in central and peripheral
nervous system synaptic function (Aldridge
et al. 2004; Meyer et al. 2004), for structural
abnormalities such as cortical thinning (Byers
et al. 2005), for tests of cognitive performance
(Aldridge et al. 2005; Levin et al. 2002), and
for locomotor activity (Dam et al. 2000). For
DZN, given the additional participation of
sex-selective effects on AChE-S, we would
anticipate even stronger sex-selectivity of
neurotoxic outcomes. Perhaps just as critically,
even in the control group we found substan-
tially higher expression of AChE-S in males
than in females. This type of underlying dif-
ference in the “neurotoxic” variant of AChE
may thus contribute to greater vulnerability of
neonatal males to neurotoxicant injury in
general and not just to the OP pesticides. In
sum, our results support the idea that non-
enzymatic functions of AChE splice variants
are involved in the mechanisms for the
developmental neurotoxicity of OPs, and that
the various OPs differ in the degree to which
they recruit this mechanism.
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